Field evaluation of the efficacy and the safety of a combination of oxantel/pyrantel/praziquantel in the treatment of naturally acquired gastrointestinal nematode and/or cestode infestations in dogs in Europe.
In five multicentre field trials, the efficacy and safety of a combination of oxantel/pyrantel/praziquantel (Dolpac), Vetoquinol SA) in the treatment of naturally acquired gastrointestinal nematode and/or cestode infestation in dogs was evaluated in northern and southern Europe. Forty-eight investigators from France, Belgium, Germany, Italy and Spain enrolled 329 dogs to be treated with the tested combination; 235 of these dogs complied with the inclusion criteria of the protocol and had a tested helminth identified on Day 0. A pooled analysis was performed on each of the following helminth species: Toxocara canis, Ancylostoma caninum, Toxascaris leonina, Trichuris vulpis, Uncinaria stenocephala, Taenia spp. and Dipylidium caninum, which were isolated on Day 0. The main efficacy criterion was the egg per gram (epg) percent reduction of the nematodes and the absence of proglottids and or eggs for the cestodes. After treatment, dogs were examined on Day 7, Day 14 and Day 21. The efficacy of the combination against Toxocara canis was 99.1%, 98.8% and 98.9% on Day 7, Day 14 and Day 21, respectively. At the same occasions the efficacy was, respectively, 99.2%, 99.2% and 99.3% against Ancylostoma caninum, 97.3%, 97.2% and 98.4% against Trichuris vulpis, 98.4%, 98.8% and 98.8% against Uncinaria stenocephala, 98.9%, 99.5% and 99.9% against Toxascaris leonina, 97.1%, 100% and 100% against Dipylidium caninum and 100% against Taenia spp.
Grandemange
E
E
VETOQUINOL Research Centre, BP189, 70204 LURE Cedex, France. erik.grandemange@vetoquinol.com
Claerebout
E
E
Genchi
C
C
Franc
M
M
D000818:Animals; D000871:Anthelmintics / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D002590:Cestode Infections / Q000188:drug therapy / Q000453:epidemiology / Q000662:veterinary*; D004283:Dog Diseases / Q000188:drug therapy* / Q000453:epidemiology; D004285:Dogs; D004338:Drug Combinations; D005060:Europe / Q000453:epidemiology; D005243:Feces / Q000469:parasitology; D005260:Female; D008297:Male; D009349:Nematode Infections / Q000188:drug therapy / Q000453:epidemiology / Q000662:veterinary*; D011223:Praziquantel / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D011715:Pyrantel / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D011716:Pyrantel Pamoate / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*
D000871:Anthelmintics; D004338:Drug Combinations; D011715:Pyrantel; D011223:Praziquantel; D011716:Pyrantel Pamoate; C003407:oxantel